Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM551 in Healthy Participants
NCT07900945Phase 1Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM551 in inflammatory bowel disease (IBD) (4 arms), sponsored by Keymed Biosciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1.5 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CM551
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07900945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900945.